FDA
-
-
-
-
-
-
-
Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives
-
-
-
-
-
-
-
Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter baumannii
-
-
-
-
-
-
-
Recce Pharmaceuticals Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
-
-
-
-
-
-
-
Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
-
-
-
-
-
-
-
Recce Pharmaceuticals Awarded AusIndustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program
-
-
-
-
-
-
-
Recce Pharmaceuticals Secures $8M Placement and Launches $3M Entitlement Offer to Shareholders
-
-
-
-
-
-
-
Recce Pharmaceuticals Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives
-
325,844 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

